Ryvu Therapeutics is a Polish biotechnology company based in Krakow that has been conducting scientific research for many years with the goal of developing new anti-cancer therapies for diseases such as acute myeloid leukemia (AML), high-risk myelodysplastic syndromes (HR-MDS), low-risk MDS, bone marrow fibrosis – myelofibrosis, and diffuse large B-cell lymphoma (DLBCL).

Every day, over 200 highly qualified scientists and experts at Ryvu begin their workday with a mission to continuously push the boundaries of science in hopes of improving the quality of life for patients facing cancer.
Fighting cancer is an immense challenge—not only for the patients themselves but also for their families and physicians. Chemotherapy is often the first thing that comes to mind for cancer patients. While this method can be effective, it is associated with side effects and does not guarantee a cure.

Ryvu is committed to finding new, safer, more effective, and more precise treatment methods, focusing primarily on targeted therapy. This type of therapy aims to combat cancer cells without simultaneously damaging healthy tissues.

Ryvu’s research projects are carried out in collaboration with international research centers and pharmaceutical companies to accelerate the development of these therapies.
It’s important to note that while Ryvu Therapeutics’ research shows promise, it is currently in various phases of clinical trials. This means the drugs are not yet widely available, and there is no guarantee they will become fully effective treatments in the future. However, participation in clinical trials may represent a new therapeutic option for some patients.

With patient safety as a top priority, such decisions should always follow detailed medical consultation. Currently, Ryvu’s clinical trials are being conducted in Poland, Germany, France, Spain, Italy, as well as in the United States and Canada.

Through daily collaboration among patients, physicians, and scientists, Ryvu is steadily paving the way toward the development of groundbreaking cancer therapies.
For more information about Ryvu Therapeutics’ scientific progress and ongoing clinical trials, visit:

www.ryvu.com